GSK GlaxoSmithKline
- 34.330
- +0.310+0.91%
- 34.250
- -0.080-0.23%
GlaxoSmithKline News
European Commission Approves Products by BeiGene, GSK and Novartis
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Express News | GSK's Fully Liquid Menveo Meningococcal Vaccine Approved By European Commission
GSK's Liquid Meningitis Vaccine Gets EU Authorization
Bird Flu Found In Raw Milk Leads To Recall In California
Alector/AbbVie-Partnered Alzheimer's Drug Disappoints In Mid-Stage Study; Alector Lays Off 17% Of Workforce
FDA Accepts GSK's BLA for Blenrep Combos in Multiple Myeloma
Optimistic Buy Rating for GlaxoSmithKline: Undervalued Stock With Promising Growth Prospects
Goldman Sachs Sticks to Its Hold Rating for GlaxoSmithKline (GSK)
GSK Cancer Therapy Candidate Accepted for FDA Review
Blenrep Combinations Accepted for Review by the US FDA for the Treatment of Relapsed/refractory Multiple Myeloma
GSK's RSV Vaccine Approved for Japanese Patients in Their 50s
Arexvy Approval Expanded to Adults Aged 50-59 at Increased Risk of Severe RSV Disease in Japan
Optimism Over Global Healthcare Sector Rises: Jefferies
Vicebio Advances Clinical Study of RSV/hMPV Bivalent Vaccine & Strengthens Board With Appointments of World Class Veterans
CDC Warns Against a Spike in COVID, Flu Cases
GSK Drug for Rare Disease-Related Itch Meets Goal in Phase III Study
Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
glaxosmithkline (GSK.US) IBAT inhibitor successfully treats PBC-related cholestatic pruritus phase III study
On November 19, glaxosmithkline (GSK.US) announced that the phase III GLISTEN study has achieved positive results.
GSK Says Trial of Itch Treatment Linerixibat Meets Primary Endpoint
Analysis
Price Target
No Data
No Data
